NGM Bio to Present at Two Upcoming Investor Conferences
July 31 2020 - 8:00AM
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology
company focused on discovering and developing transformative
therapeutics for patients, today announced that David J. Woodhouse,
Ph.D., Chief Executive Officer, will present an overview of the
company and provide a business update at two upcoming investor
conferences.
Monday, August 10, 2020
Event: BTIG Biotechnology Conference 2020 Time: 11:00
am ET
Thursday, August 13, 2020
Event: Canaccord Genuity 40th Annual Growth Conference Time:
9:00 am ET
A live webcast of these presentations will be
available under the Investors and Media section of NGM’s website at
https://ir.ngmbio.com/events-presentations. A replay of the
presentation will be archived on NGM’s site for 30 days following
the event.
About NGM Biopharmaceuticals,
Inc. NGM is a biopharmaceutical company focused on
discovering and developing novel therapeutics based on scientific
understanding of key biological pathways underlying liver disease,
retinal disease, cancer and metabolic disease. We leverage our
biology-centric drug discovery approach to uncover novel mechanisms
of action and generate proprietary insights that enable us to move
rapidly into proof-of-concept studies and deliver
potential first-in-class medicines to patients. At NGM,
we aspire to operate one of the most productive research and
development engines in the biopharmaceutical industry, with
multiple programs in clinical development. Visit us
at www.ngmbio.com for more information.
Investor Contacts: Sylvia Wheeler and Alexandra
Santosswheeler@wheelhouselsa.comasantos@wheelhouselsa.comir@ngmbio.com |
Media Contact: Liz Melonemedia@ngmbio.com |
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Apr 2024 to May 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From May 2023 to May 2024